drugset / Trial / NCT02338921
Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy
RandomizedParallel-groupTriple-blindTreatment
Summary
To assess the efficacy of treatment with sitagliptin or dapagliflozin or lobeglitazone in type 2 diabetes mellitus patients, who had inadequate glycemic control even though use of two drug combination therapy with glimepiride and metformin.
Timeline
- Start
- 2015-01
- Primary completion
- 2021-11-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | Oral |
| Comparator | Lobeglitazone | Small molecule | 0.5 mg | Oral |
| Comparator | Sitagliptin | Small molecule | 100 mg | Oral |
| Comparator | Glimepirde | Unknown | — | — |
| Comparator | Metformin | Small molecule | — | — |